Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Denali Therapeutics Inc.NASDAQ: DNLI

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 187.31M shares rose 9.3% year over year, ahead of the +5.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.3% holds above the trailing-twelve-month pace of +5.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
187.31M+0.4% QoQ
Last fiscal yearDec 2025
175.46M+6.7% YoY
LTMJun 2026
180.46M+5.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.3%——
1 year+6.7%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
175.46M USD
Year-over-year change
+6.7%
4-year CAGR
+9.6%

Weighted Avg Shares vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's LTM Jun 2026 weighted avg shares of 180.46M shares is the highest of the 11 companies compared; the peer median is 102.39M shares.
  • Its year-over-year change of +5.8% is the 8th highest of 11, against a peer median of +29.5%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of +22.6%.
DNLI Competitors Peer median
Weighted Avg Shares for DNLI and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026108.82M +29.3%+12.4%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026100.65M +1.1%+1.3%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
PMNProMIS Neurosciences, Inc.LTM Jun 20264.71M +249.7%+80.2%
Peer median (excluding DNLI) 102.39M+29.5%+22.6%

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.66M108.46M330.53M00
Cost of Revenue000011.18M
Gross Profit48.66M108.46M330.53M0(11.18M)
Gross Margin100.0%100.0%100.0%——
Research & Development265.35M358.73M423.88M396.44M418.78M
Selling, General & Admin79.06M90.48M103.35M105.44M97.1M
Operating Expenses344.41M449.21M527.23M487.34M544.16M
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
EBITDA(282.56M)(315.59M)(128.47M)(492.89M)(497.63M)
EBITDA Margin-580.7%-291.0%-38.9%——
Operating Income(295.75M)(340.74M)(196.7M)(487.34M)(555.34M)
Operating Margin-607.8%-314.2%-59.5%——
Interest Income4.6M14.77M51.51M64.64M42.9M
Interest Expense00000
Other Income / Expenses4.6M14.77M51.51M64.64M42.9M
Income Before Tax(291.16M)(325.97M)(145.19M)(422.71M)(512.44M)
Pre-Tax Margin-598.3%-300.5%-43.9%——
Income Tax Expense(575K)21K30K68K102K
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Net Margin-597.2%-300.6%-43.9%——
EPS (Basic)(2.39)(2.60)(1.06)(2.57)(2.97)
EPS (Diluted)(2.39)(2.60)(1.06)(2.57)(2.97)
Weighted Avg Shares121.52M125.53M137.37M164.47M175.46M
Weighted Avg Shares (Diluted)121.52M125.53M137.37M164.47M175.46M

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.